THANK YOU FOR SUBSCRIBING
111 Creates Digitally-enabled, Omni-channel Drug Commercialization Platform to Provide Full Life-cycle Healthcare Management Solutions for Patients
As technology enters in a new digital era for healthcare, the Chinese government has instituted a number of new regulations to modernize the healthcare industry as well as to encourage the development of virtual healthcare services.
By
Apac CIOOutlook | Wednesday, October 07, 2020
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Dr. Gang YU, Co-founder and Executive Chairman of 111, said that over the next decade, the quick adaptation of digital technology in the healthcare industry would drive the sector to become the largest industry in China, surpassing the auto industry and real estate.
FREMONT, CA: 111, a leading digital healthcare platform dedicating to digitally connecting patients with drugs and healthcare services in China, conducted its 3rd annual China Online Healthcare Summit and Partnership Conference (the "Healthcare Summit") in Shanghai, China. This year's theme emphasized on "The Age of Technology and Healthcare Digitalization."
As technology enters in a new digital era for healthcare, the Chinese government has instituted a number of new regulations to modernize the healthcare industry as well as to encourage the development of virtual healthcare services. Transformative healthcare platforms that offer consumers more convenient and efficient access to healthcare plays an important role in addressing the needs of an aging population. These new regulations, including volume-based procurement policies have created many challenges to the traditional drug commercialization process, and the Healthcare Summit provided an ideal forum for industry leaders to collect and discuss these challenges as well as the innovations poised to tackle these challenges, such as 111's pioneering omni-channel platform.
The Healthcare Summit attracted nearly 600 guests globally, including executives from leading pharmaceutical and healthcare companies, government leaders, medical experts, and investment institutions. During the conference, 111, declared strategic cooperation agreements with Novartis, Huluwa Pharmaceutical, Bayer Healthcare, Shanghai Juyin Information Technology, Xiangxue Pharmaceutical, Agilent Technologies, and Zoenet (Xiamen) Health.
Dr. Gang YU, Co-founder and Executive Chairman of 111, said that over the next decade, the quick adaptation of digital technology in the healthcare industry would drive the sector to become the largest industry in China, surpassing the auto industry and real estate.
Junling LIU, Co-founder, Chairman and CEO of 111, added that as a digital healthcare platform, 111, is capable of connecting patients with medical and healthcare products and services organically through digital technologies. "111 has built an ecosystem in which we empower pharmaceutical companies, pharmaceutical distributors, pharmacies, doctors, and insurance companies through technologies."